Loading...
Loading...
Contributors:
Dataset URI:
10.6084/m9.figshare.30353446.v1Introduction: Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive sarcoma that most commonly presents in males with abdominal and peritoneal invasion. There are potential curative therapeutic options, but survival remains poor. To this day, there have only been 22 reported cases of primary renal DSRCT in the literature and thoracic DSRCT has been rarely reported with very little known about effective therapy. This is the first reported case of renal DSRCT following a primary malignancy, and it is further distinguished by the application of whole-genome sequencing and targeted biological therapy. Case Presentation: The literature on renal DSRCT was reviewed, and we describe a patient with thoracic relapse of DSRCT following a primary renal lesion, initially treated with radical nephrectomy and 14 cycles of chemotherapy (doxorubicin 225 mg/m2, cyclophosphamide 11.4 g/m2, ifosfamide 63 g/m2, etoposide 3.5 g/m2 and vincristine 12 mg/m2). The patient also had a distant history of nodular lymphocyte predominant Hodgkin Lymphoma, in remission for five years following three cycles of doxorubicin 150 mg/m2, vincristine 8.4 mg/m2, prednisone 840 mg/m2, and cyclophosphamide 2.4 g/m2. Treatment with pazopanib for DSRCT was attempted but discontinued due to significant toxicity. Conclusion: Desmoplastic small round cell tumor (DSRCT) remains a highly aggressive malignancy with limited treatment options and poor prognosis. Our case highlights the rarity of primary renal DSRCT and its potential for thoracic relapse, further emphasizing the challenges in disease management.
Keyword(s):
Medicine; Medicine.
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)